In this free webinar, learn about the importance of customizing randomization and trial supply management (RTSM) site resupply algorithms to balance investigational medicinal product (IMP) supply security and cost. Attendees will learn how advanced RTSM platforms enable sponsors to choose from a portfolio of resupply strategies tailored to individual trial needs. The featured speakers will discuss the critical role of collaboration between sponsors and RTSM vendors in optimizing site resupply algorithms. Attendees will learn best practices for selecting and implementing the most effective resupply strategy to reduce waste and costs while ensuring supply security.
TORONTO, Nov. 5, 2024 /PRNewswire-PRWeb/ -- In clinical trials, managing investigational medicinal product (IMP) supply is critical to ensuring trial success. The interactive response technology (IRT) site resupply algorithm is a key component of this process, designed to balance two major considerations: risk (the security of IMP supply) and cost (associated with IMP waste and distribution).
While traditional IRT platforms generally rely on a standard resupply algorithm that combines buffer stock levels with predictable demand forecasting, this approach may not be optimal for every clinical trial. Each trial has a unique set of factors influencing the optimal resupply strategy, including trial design, patient enrollment rates, geographic distribution and supply chain complexities.
Advanced IRT and randomization and trial supply management (RTSM) platforms offer a more flexible solution by supporting a portfolio of resupply algorithms, allowing sponsors and vendors to collaborate in identifying the algorithm that best suits the needs of a particular trial. By leveraging the sponsor's deep knowledge of the trial and the RTSM vendor's expertise in resupply capabilities, the ideal balance between risk and cost can be achieved. This collaboration is essential to tailoring the resupply strategy to the specific demands of each study, reducing IMP waste, lowering distribution costs and maintaining a secure and efficient supply chain.
This session will explore the benefits of using advanced RTSM systems to customize site resupply algorithms, highlighting the critical role of sponsor-vendor collaboration. Attendees will gain insights into how different resupply strategies can impact trial outcomes and learn best practices for implementing a more flexible and efficient approach to RTSM site resupply management.
Register for this webinar to learn how to optimize a clinical trial's resupply strategy and improve overall trial efficiency.
Join Benjamin Etschmann, Senior Forecasting Services Lead, 4G Clinical; Conor Hayes, Client Services Lead, 4G Clinical; Buz Hillman, Associate Director, Strategic Management and Systems Discovery, Product Development & Supply, Johnson and Johnson; Libbi Rickenbacher (Moderator), Sr. Director of Product Strategy and Partnerships, 4G Clinical, for the live webinar on Tuesday, November 19, 2024, at 10am EST (4pm CET/EU-Central).
For more information, or to register for this event, visit Adapting IRT Resupply Algorithms to Balance Risk and Cost.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com
SOURCE Xtalks
Share this article